BlackRock, Inc. 13D and 13G filings for TG Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-30 12:45 pm Sale | 2025-03-31 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 20,134,882 12.800% | -1,821,430 (-8.30%) | Filing |
| 2024-10-07 4:08 pm Purchase | 2024-09-30 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 21,956,312 14.200% | 11,188,149 (+103.90%) | Filing |
| 2024-01-26 4:23 pm Purchase | 2023-12-31 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 10,768,163 7.100% | 1,635,273 (+17.91%) | Filing |
| 2023-02-01 4:54 pm Purchase | 2022-12-31 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 9,132,890 6.300% | 230,725 (+2.59%) | Filing |
| 2022-02-01 5:08 pm Purchase | 2021-12-31 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 8,902,165 6.200% | 345,879 (+4.04%) | Filing |
| 2021-02-01 08:30 am Purchase | 2020-12-31 | 13G | TG Therapeutics, Inc. TGTX | BlackRock Inc. BLK | 8,556,286 6.300% | 2,527,496 (+41.92%) | Filing |